DexCom, Inc.

Dexcom Reports Third Quarter 2026 Financial Results

Dexcom reported Q3 2026 revenue of $1.344 billion, up 11% year-over-year on both a reported and organic basis, with U.S. revenue up 14%. Margins improved meaningfully: GAAP operating income rose to $327.2 million (24.3% of revenue, +420 bps) and non-GAAP EPS came in at $0.73 versus $0.61 a year ago. Management again raised full-year guidance, now targeting FY26 revenue of $5.20-$5.25 billion (~12-13% growth) with non-GAAP operating margin of approximately 24%, and the board authorized a new $1.0 billion share repurchase. Strategic highlights include publication of the CONNECT trial in NEJM supporting G7 in non-insulin Type 2 diabetes and the first two international clearances for the G7 15 Day System.

•3d ago

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

Dexcom announced that the G7 15 Day CGM system will launch in Canada in November for adults 18 and older living with type 1 and type 2 diabetes. The sensor offers up to 15.5 days of wear with an overall MARD of 8.0%, which the company describes as the longest-lasting and most accurate CGM authorized by Health Canada. Public reimbursement for many eligible Canadians and coverage from most private CGM-covering plans begin in November, and Dexcom expects automated insulin delivery integration to follow shortly. A single-country launch without disclosed financial figures, but reimbursement already in place reduces the usual launch-access risk.

•4d ago

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Dexcom announced NEJM publication of the CONNECT randomized controlled trial, the first real-time CGM clinical data the journal has published in nearly two decades. Dexcom G7 users not on insulin achieved an average 1.6% A1C reduction from a baseline of 8.8% -- 0.9% better than routine care -- and spent about five additional hours per day in the 70-180 mg/dL target range. Benefits held across subgroups including GLP-1 users, and 97% of participants were still using CGM after 26 weeks, supporting earlier CGM adoption in Type 2 diabetes and potentially broader payor coverage for Dexcom.

•18d ago

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

Dexcom released its 2026 State of Type 2 Report ahead of the EASD annual meeting in Milan, based on surveys of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries. The report highlights adoption barriers: 55% of Type 2 patients report limited CGM knowledge, and 90% of U.S. HCPs cite coverage and reimbursement challenges, while CGM users report strong outcomes including 94% managing diabetes more independently. Dexcom also announced a partnership to become the official CGM of Team Novo Nordisk, the all-diabetes professional cycling team, aimed at awareness, education, and real-world research. The release is promotional rather than financial; its relevance to investors is as a demand-signaling and brand-positioning data point around GLP-1/CGM pairing and Type 2 market expansion.

•1mo ago

Dexcom Reports Second Quarter 2026 Financial Results

Dexcom reported Q2 2026 revenue of $1.308 billion, up 13% year-over-year, with GAAP operating income increasing 590 basis points to 24.3% of revenue. Management raised FY2026 revenue guidance to $5.18-$5.25 billion and increased targets for non-GAAP gross profit, operating, and EBITDA margins. Strategic highlights included positive results from the CONNECT randomized controlled trial for type 2 diabetes patients not using insulin and the launch of the reimagined Stelo app experience with AI-driven insights.

•3mo ago

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

Dexcom is the first company selected for the FDA's TEMPO pilot program, a new initiative designed to evaluate digital health technologies for chronic disease management and generate real-world evidence. The pilot allows Dexcom to implement an AI-powered glucose health program integrating data from Dexcom G7 and Stelo to aid in the screening of prediabetes and Type 2 diabetes. This participation aims to support earlier intervention strategies and potentially expand access to glucose biosensing technologies by validating their clinical utility through the FDA's framework.

•3mo ago

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom received Health Canada authorization for the Dexcom G7 15 Day system for adults 18 years and older living with diabetes. The new system offers an industry-leading 15.5 days of wear and a best-in-class MARD accuracy of 8.0%, reducing the frequency of sensor changes required per month. While authorized, the product is not yet available for purchase as the company focuses on establishing support and education infrastructure for Canadian healthcare providers and patients.

•3mo ago

Dexcom Further Advances Vision of Glucose Biosensing for All

Dexcom received FDA clearance to expand the indication for its Stelo Glucose Biosensor to include children ages 2 and older not using insulin, significantly widening its addressable market in the US. The company will launch a fully reimagined Stelo app experience in July for US users, designed to make glucose insights more approachable and actionable. International expansion is also planned, with Stelo availability slated for the UK, Australia, New Zealand, and South Korea starting later this year and continuing into 2027.

•4mo ago

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Dexcom announced positive results from the CONNECT randomized controlled trial, showing that Dexcom G7 leads to a clinically significant 1.6% average A1C reduction in Type 2 diabetes patients not using insulin. The study demonstrated a 0.9% greater A1C reduction compared to the control group using self-monitoring of blood glucose, with even larger benefits (3.1% reduction) for patients with baseline A1C >10%. These results provide Level A evidence, the highest grade by the ADA, supporting CGM as the standard of care for this large patient population, potentially expanding the addressable market and reimbursement landscape.

•4mo ago

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

Dexcom announced an agreement to acquire Nutrisense, a move designed to integrate personalized nutrition education and coaching into its diabetes management ecosystem. The company also highlighted the early access launch of a reimagined Stelo app, which received FDA clearance and features AI coaching and pattern recognition for non-insulin users. Additionally, Dexcom will present results from the CONNECT randomized controlled trial at the ADA Scientific Sessions, demonstrating CGM benefits for adults with Type 2 diabetes not on insulin.

•4mo ago

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Dexcom announced the launch of Dexcom Flex in Germany, a new continuous glucose monitoring system designed for adults with Type 2 diabetes who are not using intensive insulin therapy. The device targets patients using basal insulin, oral medications, or GLP-1 receptor agonists, aiming to expand CGM access to a broader patient population that has historically had limited access. Dexcom executives stated the launch reflects a shift toward personalized diabetes guidance, supporting patients earlier in their Type 2 journey to improve long-term health outcomes and reduce complications.

•5mo ago

Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

Dexcom announced governance enhancements ahead of its 2026 Investor Day, including the addition of two new independent directors with MedTech and operations experience. The company also reconstituted its Technology Committee into an Operations and Innovation Committee to better oversee scaling, quality, and the technical roadmap. These initiatives follow constructive engagement with activist investor Elliott Management, which cited conviction in Dexcom’s long-term growth and margin expansion potential.

•5mo ago

Dexcom Reports First Quarter 2026 Financial Results

Dexcom reported Q1 2026 revenue of $1.192 billion, representing 15% year-over-year growth on a reported basis, driven by healthy demand for its CGM systems. Profitability improved significantly, with GAAP operating income rising 850 basis points to 21.4% of revenue and non-GAAP operating income reaching $264.4 million. The company raised its fiscal 2026 guidance for Non-GAAP Operating Margin to approximately 23-23.5% and Adjusted EBITDA Margin to 31-31.5%, while reiterating its revenue outlook of $5.16 to $5.25 billion.

•6mo ago